

AmeriHealth Caritas Louisiana

*National Imaging Associates, Inc. *	
Clinical guidelines PET SCANS includes <ul style="list-style-type: none"> • PET • PET with CT Attenuation • PET/CT 	Original Date: September 1997
78811 Limited area e.g. Chest, head/neck 78812 Skull base to mid thigh 78813 Whole Body 78814 With CT attenuation (Limited area e.g. Chest, head/neck) 78815 With CT attenuation (Skull base to mid thigh) 78816 With CT attenuation (Whole Body)	Last Revised Date: May 202 2 ³
Guideline Number: NIA_CG_070-1	Implementation Date: January 202 3 ⁴

GENERAL INFORMATION

- It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.
- Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.

GENERAL NOTES:

ADULT AND PEDIATRIC MALIGNANCIES¹

ONCOLOGICAL PET IS INDICATED FOR BIOPSY-PROVEN CANCER **OR** STRONGLY SUSPECTED CANCER BASED ON OTHER DIAGNOSTIC TESTING. The appropriateness of an ordered PET/CT study is dependent on which radiopharmaceutical will be used for the PET/CT.

*National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

INDICATIONS FOR FDG PET:

See Legislative Requirements for specific mandates for the State of Washington

The following list applies to biopsy-proven cancers AND lung nodules with no known history of malignancy. This is NOT a comprehensive list. Additional indications for PET are found in the tables following this list. The definitions regarding initial staging and restaging (including time interval following treatment**) apply.

- Solid lung nodule > 8 mm and no prior PET – Indicated
- Mixed lung nodule* with solid component > 6 mm and no prior PET – Indicated
- Basal cell carcinoma of the skin – Not indicated for initial staging or restaging
- Castleman's Disease – Indicated for initial staging and restaging
- Cervical Cancer (stage IB1 or higher) – Indicated for initial staging and restaging**
- Chondrosarcoma – Not indicated for initial staging or restaging
- Ewing's Sarcoma* – Indicated for staging (all ages) and restaging age < 30
- Head and Neck Cancer – Indicated for initial staging and restaging**
- Non-Small Cell Lung Cancer – Indicated for initial staging and restaging
- Lymphoma (Hodgkin's and non-Hodgkins) – Indicated for initial staging and restaging
- Melanoma* – cutaneous – (stage III, IV) – indicated for initial staging and restaging
- Merkel Cell – Indicated for initial staging and restaging
- Osteosarcoma* – Indicated for initial staging (all ages) and restaging age < 30
- Peritoneal Mesothelioma – Indicated for initial staging and restaging
- Post Transplant Lymphoproliferative Disorder (PTLD) – indicated for initial staging and restaging
- Renal – Not indicated for initial staging or restaging
- Rhabdomyosarcoma (RMS) – Indicated for initial staging and restaging
- Small bowel carcinoma* – Not indicated for initial staging
- Soft Tissue Sarcoma* (other than RMS) – Indicated for initial staging (age < 30) and restaging (age < 30)
- Testicular Cancer – Seminoma* – Not indicated for initial staging
- Testicular Cancer – Non-Seminoma – Not indicated for initial staging or restaging
- Thymoma/Thymic Cancer – Indicated for initial staging and restaging

*See additional indications in table below

**If radiation or chemoradiation were given, 12 weeks must have elapsed since last radiation treatment. See table below for additional indications if < 12 weeks.

INDICATIONS FOR SPECIAL TRACER PET:

The following list applies to for biopsy-proven cancers for which a non-FDG tracer (special tracer) is indicated in the specific clinical scenarios described. This is NOT a comprehensive list. Additional indications for non-FDG PET are found in the tables following this list. The definitions regarding initial staging and restaging (including time interval following treatment**) apply. Diagnosis needs to be confirmed by biopsy and tracer planned clearly indicated.

- Prostate Cancer* – PSMA PET Indicated for initial staging ONLY of non-metastatic² Gleason 8, 9, 10 disease (or grade group 3, 4 or 5 disease)
- Carcinoid, Well-differentiated Neuroendocrine tumors, pheochromocytoma and paraganglioma* – SSTR PET (such as Ga68-Dotatate, Ga68-Dotattoc and Cu64-Dotatate) Indicated for initial staging ONLY

FDG-PET/CT (fluorodeoxyglucose-positron emission tomography)

LUNG NODULE ~~seen on LDCT or CT+ contrast (without known malignancy)~~
LUNG NODULE³ seen on LDCT or CT+ contrast (without known malignancy)

- Solid Component of Dominant Nodule (either solitary or clearly dominant) ≥ 8mm ~~and <3cm or Part solid/mixed nodules with the solid component 8 mm or larger~~OR
- Part solid/mixed nodules with the solid component 6 mm or larger OR
- Mixed nodule (i.e., ground glass and solid nodule) with solid component of the nodule ≥ 4mm on LDCT when there has been
 - Interval growth of the solid component of at least 1.5mm on subsequent LDCT scans

OR

 - Interval development of a new mixed nodule on subsequent LDCT with the solid nodule component ≥ 4mm

FDG PET

ONCOLOGICAL INDICATIONS FOR FDG PET (SEE SPECIAL TRACERS SECTIONS FOR INDICATIONS OTHER TRACERS)

<u>CANCER TYPE</u>	<u>INITIAL STAGING</u>	<u>RESTAGING</u>
<u>ADRENAL⁴ (other than pheochromocytoma/ paraganglioma)</u>	<u>Indicated when conventional imaging (see Background) and biochemical evaluation are highly suggestive of adrenocortical carcinoma</u>	<u>with prior indeterminate imaging</u>
		<u>Not Indicated</u>

AIDS-related KAPOSI
SARCOMA⁵

If concerns for coexisting KSHV
associated inflammatory
cytokine syndrome (KICS),
MCD, or KSHV+ lymphoma

ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL)⁶

lymphomatous extramedullary
disease

lymphomatous extramedullary
disease

ACUTE MYELOGENOUS
LEUKEMIA (AML)^{7, 8}

If suspected extramedullary
involvement

If suspected/known
extramedullary involvement

ANAL⁹

with prior indeterminate
imaging (see Background).
(can consider PET/MR^{**})

with prior indeterminate
imaging

BASAL CELL¹⁰ (BCC of the skin)

Not Indicated

Not Indicated

BILIARY TRACT CANCER¹¹
(Cholangiocarcinoma, Gall
Bladder Cancer)

With prior indeterminate
imaging

With prior indeterminate
imaging

BLADDER¹²

With indeterminate imaging
and muscle invasive disease
only when the indeterminate
finding is outside of the urinary
tract

With indeterminate imaging
and suspected metastatic
disease or recurrence outside
of the urinary tract

BONE CANCER¹³

• Chondrosarcoma

Not indicated

Not indicated

• Chordoma

With prior indeterminate
imaging

With prior indeterminate
imaging

• Ewing Sarcoma and
Osteosarcoma

Indicated (all ages)¹³;
PET can be approved in
conjunction with MR of primary
site

Age < 30: Indicated
Age > 30: Indicated for known
or suspected metastatic disease
based clinical or imaging
findings or when PET was used
for initial staging

PET can be approved in conjunction with MR of primary site (all ages)

BREAST¹⁴

See special tracer section below for FES PET

with prior indeterminate imaging

with prior indeterminate imaging

CERVICAL¹⁵

Indicated for stage IB1 and above
(can consider PET/MR^{**})

Indicated

COLORECTAL^{16, 17}

with prior indeterminate imaging OR
potentially surgically curable metastatic disease OR
when considered for image-guided liver-directed therapies

with prior indeterminate imaging (including discordance between tumor markers (CEA) and imaging) OR
potentially surgically curable metastatic disease OR
when considered for image-guided liver-directed therapies

ENDOMETRIAL¹⁸

with prior indeterminate imaging

with prior indeterminate imaging

ESOPHOGEAL and ESOPHAGOGASTRIC JUNCTION (EGJ)¹⁹
(includes EGJ tumors with epicenter < 2 cm into stomach)

Indicated if no evidence of metastatic disease

Indicated following preoperative chemoradiation or definitive chemoradiation; OR with prior indeterminate imaging

FALLOPIAN TUBE CANCER

with prior indeterminate imaging

with prior indeterminate imaging

GASTRIC²⁰
(includes EGJ tumors with epicenter >2 cm into stomach)

with prior indeterminate imaging AND no evidence of metastatic disease

with prior indeterminate imaging

GESTATIONAL TROPHOBLASTIC
CANCER²¹

with prior indeterminate
imaging

with prior indeterminate
imaging or at completion of
chemotherapy when hCG is not
a reliable marker

GIST²²

with prior indeterminate
imaging

with prior indeterminate
imaging

HEAD and NECK²³
(including mucosal melanoma
of the head and neck)

Indicated

Additionally, Face/Neck MRI
(or CT) may be indicated
concurrently with PET if needed
for surgical planning

Indicated

Additionally, Face/Neck MRI
(or CT) may be indicated
concurrently with PET 3-4
months after end of treatment
in patients with locoregionally
advanced disease or with
altered anatomy

If final PET/CT is equivocal or
borderline for residual disease,
a repeat PET/CT at > 6 weeks
may help identify those that
can be safely observed without
additional surgery

HEPATOCELLULAR²⁴

with prior indeterminate
imaging

with prior indeterminate
imaging

LEUKEMIA
(refer to specific types listed in
table when possible)

If there is lymph node
involvement (lymphomatous
features), soft tissue and/or
extramedullary involvement
(myeloid sarcoma) and/or if
forms “chloromas” (leukemia
tumor balls)

If there is lymph node
involvement (lymphomatous
features), soft tissue and/or
extramedullary involvement
(myeloid sarcoma) and/or if
forms “chloromas” (leukemia
tumor balls)

LUNG

• <u>Non-Small Cell</u> ²⁵	<u>Indicated</u>	<u>Indicated</u>
• <u>Limited stage small cell</u> ²⁵	<u>Indicated</u>	<u>Indicated prior to radiation or with indeterminate imaging</u>
• <u>Extensive stage small cell</u>	<u>Not indicated unless conventional imaging is unable to conclusively classify the stage as extensive (see Background)</u>	<u>Not indicated unless consolidative thoracic radiation is planned (see Background)</u>
<u>LYMPHOCYTIC LEUKEMIA</u>		
• <u>Chronic (CLL) and Small (SLL)</u> ²⁶	<u>For suspected high-grade transformation or to guide biopsy with prior indeterminate imaging</u>	<u>with accelerated CLL or to guide biopsy with prior indeterminate imaging (includes negative CT with rising tumor markers or if conventional imaging documents mets, IF clearly considering resection)</u>
<u>LYMPHOMA (Non-Hodgkins and Hodgkins)</u> ²⁷⁻³²	<u>Indicated (can consider PET/MR^{**})</u>	<u>Indicated (can consider PET/MR^{**})</u>
<u>MELANOMA</u>		
• <u>Cutaneous</u> ³³	<u>stage III, IV indicated; indicated for dermal melanomas that lack epidermal involvement</u>	<u>Indicated for stage III, IV disease OR for workup of local satellite/in-transit and/or nodal recurrences (see Background)</u>
• <u>Uveal</u> ³⁴	<u>Not indicated</u>	<u>With prior indeterminate imaging</u>
<u>MERKEL CELL</u> ³⁵	<u>Indicated</u>	<u>Indicated</u>

MESOTHELIOMA (malignant)

- Pleural³⁶

Indicated for stage I-IIIa when the patient is a potential surgical candidate (see Background)

Indicated only prior to surgery for stage I-IIIa

- Peritoneal³⁷

Indicated

Indicated

MULTIPLE MYELOMA³⁸

- Smoldering myeloma (asymptomatic)

Indicated

Indicated annually or possibly more frequently as clinically indicated (labs and/or symptoms to suggest progression)

- Active myeloma

Indicated

Indicated

- Plasmacytoma

Indicated

Indicated

NEUROBLASTOMA

Indicated when MIBG is negative, indeterminate, or there are discordant findings between MIBG and pathology

Indicated when FDG PET was used for initial staging or if MIBG has become indeterminate or discordant

NEUROENDOCRINE TUMORS:³⁹

- Poorly differentiated

with prior indeterminate imaging (see Background)

with prior indeterminate imaging (see Background)

- Well-differentiated grade 3 with high Ki-67 ($\geq 55\%$)

Indicated after prior negative or indeterminate SSTR (dotatate) PET (see Background)
with prior indeterminate imaging

Indicated after prior negative or indeterminate SSTR (dotatate) PET (see Background)
with prior indeterminate imaging (including discordance between tumor markers (CA-125) and imaging)

OVARIAN⁴⁰

with prior indeterminate imaging

with prior indeterminate imaging (including discordance between tumor markers (CA-125) and imaging)

OCCULT PRIMARY⁴¹

with prior indeterminate imaging (see Background)

with prior indeterminate imaging (see Background)

PANCREATIC

With prior indeterminate imaging
OR with any of the following high-risk features:

- borderline resectable disease
- markedly elevated CA19-9 >180 U/ml
- large primary tumor/lymph nodes
- very symptomatic (jaundice, symptomatic gastric outlet obstruction, venous thromboembolism, extreme pain and excessive weight loss)

When PET was used for initial staging and need to assess response to treatment in order to determine if now a surgical candidate

PENILE⁴²

with prior indeterminate imaging

with prior indeterminate imaging

PERITONEAL CANCER⁴⁰ (PRIMARY)

with prior indeterminate imaging

with prior indeterminate imaging

POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)

Indicated when the diagnosis is made OR if suspected based on abnormal PE, abnormal imaging or abnormal labs (i.e., significantly elevated or rising viral titers)

Indicated

PROSTATE (FDG PET only) (see Prostate Special Tracer section)

Not Indicated

Not Indicated

RENAL⁴³

Not indicated

Not indicated

<u>SKIN SQUAMOUS CELL⁴⁴</u>	<u>Indicated for biopsy proven \geqN1 or \geqM1 disease (lymph node or metastatic site has been biopsied and shows disease spread)</u>	<u>Indicated for biopsy proven \geqN1 or \geqM1 disease (lymph node or metastatic site has been biopsied and shows disease spread)</u>
<u>SMALL BOWEL CARCINOMA⁴⁵</u>	<u>Not indicated</u>	<u>with prior indeterminate imaging</u>
<u>SOFT TISSUE SARCOMA⁴⁶</u>		
• <u>Rhabdomyosarcoma</u>	<u>Indicated</u>	<u>Indicated</u>
• <u>All other soft tissue sarcomas</u>	<u>For patients <30 years old: Indicated</u>	<u>For patients < 30 yrs old: Indicated</u>
	<u>For patients >30 years old: with prior indeterminate imaging</u>	<u>For patients <30 yrs old: with prior indeterminate imaging</u>
<u>TESTICULAR⁴⁷</u>		
• <u>Seminoma</u>	<u>Not Indicated</u>	<u>with prior indeterminate imaging OR residual mass >3cm with normal AFP and beta-hcG and 6 weeks post chemotherapy (If this final PET/CT is equivocal or borderline for residual disease, an additional repeat PET/CT > 6 weeks later may help</u>
		<u>identify those that can be safely observed without additional surgery)</u>
		<u>Not Indicated</u>
• <u>Non-Seminoma</u>	<u>Not Indicated</u>	
<u>THYMOMA/THYMIC CANCER⁴⁸</u>	<u>Indicated</u>	<u>Indicated</u>

THYROID⁴⁹

• <u>Papillary, Follicular, Oncocytic (formerly Hurthle Cell)</u>	<u>Not Indicated</u>	<u>with prior indeterminate imaging (including discordance between tumor markers (Tg, anti-Tg Ab) and imaging; see Background)</u>
• <u>Anaplastic</u>	<u>Indicated</u>	<u>Indicated</u>
• <u>Medullary</u>	<u>Not Indicated (see SSTR indications below)</u>	<u>With prior indeterminate imaging (including discordance between tumor markers (calcitonin, CEA) and imaging; see Background)</u>
<u>UTERINE (Endometrial Carcinoma and Uterine Sarcoma)⁵⁰</u>	<u>with prior indeterminate imaging</u>	<u>with prior indeterminate imaging</u>
<u>VULVAR⁵¹</u>	<u>Indicated if \geq T2 (extension beyond vulva/perineum) OR with prior indeterminate imaging</u>	<u>Indicated</u>

MISCELLANEOUS INDICATIONS FOR FDG PET

(excluding brain and cardiac PET which have separate Guidelines)

<u>TYPE</u>	<u>INITIAL STAGING</u>	<u>RESTAGING</u>
<u>CASTLEMAN'S DISEASE</u>	<u>Indicated</u>	<u>Indicated</u>
<u>HISTIOCYTIC NEOPLASMS⁵²:</u>		
• <u>Langerhan's</u>	<u>Indicated</u>	<u>Indicated if on active treatment for multiple bone disease, high risk bone disease or multisystem involvement</u>
• <u>Erdheim Chester</u>	<u>Indicated</u>	<u>Indicated if on active treatment</u>

MISCELLANEOUS INDICATIONS FOR FDG PET

(excluding brain and cardiac PET which have separate Guidelines)

TYPE	INITIAL STAGING	RESTAGING
Rosai-Dorfman	Indicated	Indicated if on active treatment

† SARCROIDOSIS

- [ONLY if conventional testing \(CXR, CT and inflammatory serology\) remain indeterminate for known sarcoid to determine:](#)
 - [if treatment might be helpful](#)
 - [extent of disease, if it will potentially change management](#)
 - [response to treatment](#)
- [OR if strongly suspected sarcoid to determine most suitable site to biopsy](#)

† VASCULITIS

- [In limited circumstances, with known vasculitis, AFTER conventional imaging \(MRA/CTA/MR/CT\) has clearly been shown to be insufficient to determine treatment](#)

† NEUROFIBROMATOSIS TYPE 1⁵³⁻⁵⁶

- [When there is a concern for transformation of a neurofibroma to a Malignant Peripheral Nerve Sheath Tumor \(MPNST\) based on a change in imaging \(such as rapid growth or change in texture on exam or imaging\) and/or symptoms \(new or worsening pain in the location of a known neurofibroma\), then a single FDG-PET is indicated \(see Background\).](#)
- [Restaging of a known MPNST with PET requires indeterminate imaging prior to PET approval.](#)

† [Adjudications should occur on a case-by-case basis](#)

YTTRIUM-90 (Y90)

[Y90 PET SCAN: Indicated when performed immediately after treatment of liver malignancy \(primary or metastatic\). The Y90 treatment is also the tracer for this and PET is performed within 24 hours of treatment \(while Y90 is still detectible\) to confirm the final distribution of the Y90. PET.](#)

NON FDG PET TRACERS

[Somatostatin Receptor \(SSTR\) PET FOR NET \(Neuroendocrine Tumors\)](#)
[\(GA68-DOTATATE, GA68-DOTATOC and CU64-DOTATATE\)](#)

CANCER TYPE	INITIAL STAGING	RESTAGING
	Indicated	

Somatostatin Receptor (SSTR) PET FOR NET (Neuroendocrine Tumors)
(GA68-DOTATATE, GA68-DOTATOC and CU64-DOTATATE)

<u>CANCER TYPE</u>	<u>INITIAL STAGING</u>	<u>RESTAGING</u>
<u>CARCINOID,NEUROENDOCRINE TUMORS (NET)⁵⁷ OF THE GI TRACT, PANCREAS, LUNG, THYMUS AND UNKNOWN PRIMARY, PHEOCHROMOCYTOMA, PARAGANGLIOMA</u>	<u>(PET/MR^{††} can be considered)</u>	<u>Indicated when there is progression or recurrence is known or suspected (based on labs and/or conventional imaging) and SSTR directed therapy is being considered (see Background)</u> <u>(PET/MR^{††} can be considered)</u>
<u>MEDULLARY THYROID</u>	<u>with prior indeterminate imaging</u>	<u>with prior indeterminate imaging (including discordance between tumor markers (calcitonin, CEA) and imaging; see Background)</u>

FES (fluoroestradiol F 18 (Cerianna®)) PET

<u>CANCER TYPE</u>	<u>INITIAL STAGING</u>	<u>RESTAGING</u>
<u>BREAST CANCER</u>	<u>Not Indicated</u>	<u>Indicated for biopsy proven recurrent or metastatic Estrogen Receptor Positive (ER-positive) disease when receptor status of sites of disease will result in a change treatment (see Background)</u>

PSMA TRACERS (such as F18 piflufolastat (Pylarify®), GA 68 PSMA-11, GA 68 gozetotide (Locametz®), and GA 68 gozetotide (Illuccix®))

For PROSTATE CANCER^{2, 58}

<u>CANCER</u>	<u>INITIAL STAGING</u>	<u>RESTAGING</u>
----------------------	-------------------------------	-------------------------

PROSTATE CANCER

TRACERS:

Initial staging: PSMA is the ONLY tracer potentially approvable for initial staging

Restaging: PSMA is the preferred tracer, see Background for other tracers such as Axumin® and 11-Choline⁵⁸.

PSMA PET is indicated for initial staging of non-metastatic² very high risk, high risk and unfavorable intermediate risk prostate cancer (see Background) (can consider PET/MR^{††})

Pelvic MRI may be indicated concurrently if needed for surgical planning

PSMA PET is indicated in the following situations (see Background):

Post-radical prostatectomy:

- For PSA persistence: detectable PSA (0.1 ng/mL or greater) at 3 months post-operatively (only one level required)

- For rising PSA on two or more occasions OR a rise to > 0.1 ng/mL if was previously undetectable

For known metastatic disease with progression on treatment and either:

- Rising PSA (on two consecutive levels)
- Disease progression on imaging (i.e. bone scan)

A single restaging PSMA PET 12 weeks after treatment with radioligand therapy (Lu-177/Pluvicto) is indicated

LEGISLATIVE REQUIREMENTS

- Washington

- Washington State Health Care Authority Health Technology Assessment 20181116B Positron Emission Tomography (PET) scans for lymphoma⁵⁹

- PET scans (i.e., PET with computed tomography or PET/CT) for lymphoma is a covered benefit with conditions.
 - An initial staging scan is covered followed by up to three (3) scans per active occurrence of lymphoma:
 - When used to assess a response to chemotherapy, scans should not be done any sooner than three (3) weeks after completion of any chemotherapy cycle, except for advanced stage Hodgkin's lymphoma, after four (4) cycles of ABVD chemotherapy.
 - When used to assess response to radiation therapy, scans should not be done any sooner than eight (8) weeks after completion of radiation or combined chemotherapy and radiation therapy.

- Relapse: Covered when relapse is suspected in the presence of clinical symptoms or other imaging findings suggestive of recurrence
- Surveillance: Not covered

Washington State Health Care Authority oversees the Apple Health (Medicaid) program and the Public Employees Benefits Board (PEBB) Program⁶⁰

BACKGROUND

~~NOTE: >3cm is considered a MASS; therefore, a tissue type is usually needed prior to PET (to determine if SCLC or NSCLC). However, if the chest CT imaging findings meet criteria for limited stage SCLC and no prior imaging shows metastatic disease elsewhere, PET can be approved prior to biopsy in order to guide biopsy of any FDG-avid adenopathy at the same time the primary is biopsied. If disease clearly is in both sides of the chest and/or outside the chest, then PET is not needed/approvable prior to tissue diagnosis.~~

USEFUL DEFINITIONS ~~(to aid in using the following table(s))~~: The cancer specific details for adjudication still apply.

- **INITIAL STAGING** refers to imaging that is performed AFTER the diagnosis of cancer is made, and generally before any treatment.
- **RETAGING** includes scans that are either needed **during active treatment*** ~~(subsequent treatment strategy**))~~ to determine response to treatment, /monitor treatment, a single end of treatment study done within 6 months ~~after the end of completion~~ of treatment, or when there is clinical **concern for recurrence** (i.e., new imaging, new signs, rising labs/tumor markers or symptoms relative to type of cancer and entire clinical picture) (recurrence is not required to be biopsy proven)
- ***ACTIVE TREATMENT** includes ~~traditional~~ chemotherapy, immunotherapy, radiation, as well as patients on “maintenance therapy” who have known, or existing, metastatic disease being held in check by this treatment. Allogenic bone marrow transplant and CART T-cell therapy should be considered ‘active’ treatment for at least 6 months after infusion/transplant and as such can be approved at 30 days, 100 days, and 6 months after the most recent infusion.
- ****SUBSEQUENT TREATMENT STRATEGY:**
 - For restaging or monitoring response during active treatment (including immunotherapy), and/or a single evaluation after completion/cessation of therapy. The interval should **ideally**[‡] be 6-12 weeks after surgery, and 12 weeks after radiation (to avoid false positive findings that can be caused by treatment changes or healing).
 - [‡]NOTE: a valid clinical reason explaining why the interval needs to be shorter than ideal must be present

- PET/CT can be performed 1 - 3 weeks after neoadjuvant chemotherapy or neoadjuvant chemoradiation if done for presurgical planning to evaluate for distant metastatic disease or to evaluate known metastatic disease located in areas separate from the site(s) being radiated.
- When an end of treatment PET scan performed at an appropriate post-treatment interval (see above) shows indeterminate findings, one additional repeat PET in 3 months is indicated.
- INDETERMINATE IMAGING: When indeterminate imaging is required prior to PET, this typically means conventional imaging (CT, MRI, OR Nuclear Medicine Scan (i.e. bone scan)) shows a finding that is indeterminate AND clarification of that finding with PET will potentially change management. When PET is not indicated for a cancer type in the guideline (i.e. literature does not support the use of PET), PET is not indicated even if indeterminate imaging is provided. The information provided should clearly explain why conventional imaging is insufficient to determine treatment or management and includes situations such as the following:
 - New or residual masses described as indeterminate on conventional imaging
 - Biopsy guidance: To determine the best location to biopsy either within a tumor that has necrosis on imaging OR to determine the best location to biopsy when there are findings on standard imaging that would require a significantly invasive procedure (such as laparoscopic or open surgical procedures) AND malignancy is highly suspected based on imaging.
- When previous conventional imaging has been shown to be negative, yet a concurrent PET scan was positive (i.e. conventional imaging was falsely negative/ missed lesions seen on PET), we do not require repeat conventional imaging prior to every subsequent PET (because conventional imaging was already shown to be insufficient). Appropriate interval criteria should still be met.

~~■ ***NOTE:** a valid clinical reason explaining why the interval needs to be shorter than ideal must be present~~

- ~~INCONCLUSIVE IMAGING see Background section at end of guidelines~~
- **SURVEILLANCE PET** is generally **not approvable**. Surveillance means no active treatment, no current suspicion of recurrence and occurs 6 months or more after completion of treatment. ~~Possible exceptions† where PET “may be considered” for surveillance:~~
 - ~~Ewing’s~~
 - ~~Osteosarcoma~~
 - ~~Breast (Stage 4)~~
 - ~~Cervical (stage 2-4)~~

- ~~Diffuse Large B Cell Lymphoma when disease was only seen previously on PET~~
 - ~~Histiocytic neoplasms every 3-6 months for the first 2 years post completion of treatment~~
 - ~~Melanoma (stage 2b-4)~~
 - ~~Myeloma/plasmacytoma (ideally use same type imaging as was used in initial dx, up to 5 yrs after the diagnosis of plasmacytoma)~~
 - ~~Seminoma (Stage 2b, 2c and 3)~~
- ~~†NOTE: These cases would need to include a clinical reason why PET is needed (i.e., being considered), rather than conventional imaging (CT, MRI, bone scan). Generally, this would be accepted only when ordered by the treating oncologist or clearly at their recommendation (not as routine follow-up ordered by PCP). Possible exceptions for the following indications only:~~

~~FDG PET~~

- Ewing's Sarcoma and Osteosarcoma in patients specified as high risk: every 3 months for 2 years, then every 4 months up to year 3 post completion of treatment.
- Small Cell Neuroendocrine Cervical every 3-6 months for the first 2 years post completion of treatment
- Diffuse Large B Cell Lymphoma when disease was only seen previously on PET: every 6 months for 2 years, then one at 12 months up to year 3 post completion of treatment.
- Gestational trophoblastic disease when hCG is not a reliable marker every 6-12 months for up to 3 years post completion of treatment
- Histiocytic neoplasms every 3-6 months for the first 2 years post completion of treatment
- Melanoma (stage 2b-4) specified as high risk every 3-12 months for 2 years, then every 6-12 months, up to 5 years after initial diagnosis^{33, 61}
- Solitary plasmacytoma (up to 3 yrs after the diagnosis of plasmacytoma)^{62, 63}

PET with CONTRAINDICATIONS to contrasted CT AND MRI:

When PET is requested for restaging due to the inability to image with contrasted conventional imaging, indeterminate non-contrasted studies must be provided prior to consideration of PET. The inability to image with contrasted conventional imaging includes

contraindications to both CT (such as chronic renal failure with GFR < 30 OR significant iodinated contrast allergy) AND to MRI (such as gadolinium allergy, implanted device that is not MRI compatible, or GFR <40). When requested for surveillance due to the above reasons, PET can be considered during the time that the highest risk of recurrence for that cancer (typically the first two years after completion of treatment).

**PET/MR: When PET/MR can be considered per the guideline, if the criteria are met for PET for that cancer and the plan is to do a PET/MR rather than a PET/CT, the PET scan can be approved. In the same way a separate approval for total body CT is not needed when a PET/CT is requested, a separate approval for the total body MR is not typically needed. However, until a PET/MR CPT code is implemented, unlisted MR in addition to PET can be considered on a case-to-case basis.

PET IN COMBINATION WITH DEDICATED SITE SPECIFIC MR (OR CT): Distinct from PET/MR, when PET is needed in addition to a dedicated site specific MRI (or CT), two authorizations may be issued: one for the PET scan and one for the site specific MRI (or CT). Clear indications for both must be provided.

STAGING: Staging for cancer is cancer-specific and is typically based on the TNM system of staging. T stage refers to the extent of the main (primary) tumor. N stage refers to the extent of spread to lymph nodes. M stage refers to whether or not the cancer has metastasized to other parts of the body. Clinical stage (such as cT2b) is determined by physical exam, imaging and possibly biopsy. Pathologic stage (such as pT2b) is determined after the tumor has been resected. Certain cancers have additional information that is needed to stage the patient (such as PSA level in prostate cancer).

CANCER SPECIFIC BACKGROUND:

Adrenal Tumors: Features of an adrenal mass on conventional imaging that are suspicious for adrenocortical carcinoma (ACC) include: size > 4 cm, inhomogenous mass with irregular margins and/or has local invasion. If there is no history of another primary malignancy and these features are present on imaging, then PET is reasonable. If there is a history of another primary tumor and a metastasis is suspected, biopsy should be done first to determine tissue type. A biochemical evaluation is also done to evaluate for other tumor types (such as pheochromocytoma) for which a different tracer (such as dotatate) may be more appropriate.

Anal Cancer: Normal pelvic lymph nodes are often not seen on imaging. When pelvic lymph nodes are visualized on imaging, even if normal in size, that finding raises concern for disease spread and can be considered indeterminate.

Brain Tumors: When an oncologic PET is requested for a primary brain malignancy, it typically should be reordered as a Brain PET (CPT 78608 and 78609). This includes requests for recurrent meningioma when dotatate PET is requested.

Breast Cancer: Fluoroestradiol F 18 (Cerianna® or FES) is a new tracer that is specific for estrogen receptor positive (ER-positive) breast cancer. It is used in recurrent or metastatic breast cancer that was known to be ER-positive at initial diagnosis to determine how much of the current disease has functional estrogen receptors. This can help determine whether endocrine therapy is appropriate. This tracer is NOT indicated for ER-negative disease. An FES PET is NOT done to monitor response to treatment but instead is done ONLY when the receptor status of the recurrent or metastatic sites is in question. FES PET is NOT used for assessing the primary site of disease.

<div>ONCOLOGICAL INDICATIONS FOR FDG PET</div> <div>(SEE SPECIAL TRACERS SECTIONS FOR INDICATIONS OTHER TRACERS)</div>		
CANCER TYPE	INITIAL STAGING	RESTAGING
ADRENAL (other than pheochromocytoma/ paraganglioma)	Not Indicated	Not Indicated
AIDS-related KAPOSI SARCOMA	with prior inconclusive imaging	Not Indicated
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	lymphomatous-extramedullary disease	lymphomatous-extramedullary disease
ACUTE MYELOGENOUS LEUKEMIA (AML)	If suspected-extramedullary involvement	If suspected/known extramedullary involvement
ANAL (Note that normal-size pelvic adenopathy can be considered as inconclusive)	with prior inconclusive imaging (can be done with PET (PET/CT or PET/MR** if available)).	with prior inconclusive imaging
BASAL CELL (BCC of the skin)	Not Indicated	Not Indicated
BLADDER	Muscle invasive only, with prior inconclusive imaging	With inconclusive imaging and suspected metastatic disease or recurrence outside of the urinary tract



BREAST	Indicated for stage IIb and above (if only T and N are provided, this equates to T3 (tumor > 50mm); or T4 (tumor of any size with direct extension to chest wall and/or skin); or N2 (>3 axillary LN, ipsilateral internal mammary node); or the combination of T2 (tumor >20mm but <50mm) plus N1 (any positive lymph node involvement)	with prior inconclusive imaging, if initial staging was performed with PET OR if recurs with IIb or higher disease (based on pathology/imaging/exam) since no previous initial staging would have typically been performed for lower grade breast cancer
CERVICAL	Indicated (can consider <u>PET/MR^{††}</u> if available)	Indicated
CHORDOMA	with prior inconclusive imaging	with prior inconclusive imaging
CHOLANGIOCARCINOMA	with prior inconclusive imaging	with prior inconclusive imaging
CHONDROSARCOMA (bone)	Not Indicated	Not Indicated
COLORECTAL	with prior inconclusive imaging OR potentially surgically curable M1 disease OR when considered for image-guided liver directed therapies	with prior inconclusive imaging
ENDOMETRIAL	with prior inconclusive imaging	with prior inconclusive imaging
ESOPHOGEAL and EGJ (esophagogastric junction epicenter < 2cm into stomach)	Indicated	Indicated

EWING SARCOMA- Osseous	Indicated (all ages)	Patients <30 yrs old: Indicated Patients >30 yrs old: Indicated for known or suspected metastatic disease (based on PE/imaging)
FALLOPIAN TUBE CANCER	with prior inconclusive imaging	with prior inconclusive imaging
GALLBLADDER	with prior inconclusive imaging	with prior inconclusive imaging
GASTRIC (include EGJ tumors with epicenter >2cm into stomach)	with prior inconclusive imaging or if radiation is being considered (Not indicated for T1N0M0 or M1)	with prior inconclusive imaging, PET/CT is indicated or for post radiation imaging
GESTATIONAL TROPHOBLASTIC CANCER	with prior inconclusive imaging	with prior inconclusive imaging
HEAD and NECK (including mucosal melanoma of the head and neck)	Indicated <ul style="list-style-type: none"> May be done in conjunction with a dedicated face/neck MRI (or CT) when surgery or radiation is planned 	Indicated <ul style="list-style-type: none"> Can concurrently approve a Neck MRI and PET 3-4 months after definitive treatment in patients with locoregionally advanced disease or with altered anatomy. PET should not be done earlier than 12 weeks after definitive treatment unless signs or symptoms of recurrence If final PET/CT is equivocal or borderline for residual disease, a repeat PET/CT at ≥ 6 weeks may help identify those that can be safely

		observed without additional surgery
HEPATOCELLULAR	with prior inconclusive imaging	with prior inconclusive imaging
LEUKEMIA (refer to specific types listed in table when possible)	If there is lymph node involvement (lymphomatous features), soft tissue and/or extramedullary involvement (myeloid sarcoma) and/or if forms “chloromas” (leukemia tumor balls)	If there is lymph node involvement (lymphomatous features), soft tissue and/or extramedullary involvement (myeloid sarcoma) and/or if forms “chloromas” (leukemia tumor balls)
LUNG		
• Non-Small Cell	Indicated	Indicated
• Limited stage small cell Stage I-III	Indicated	Indicated
○ And T3/T4 if disease is encompassed in tolerable radiation plan (potentially curable)		
• Extensive small cell	Not indicated	Not indicated
○ Stage IV and T3 or T4 disease not able to be treated with curative intent		
LYMPHOCYTIC LEUKEMIA		
• Chronic (CLL) and Small (SLL)	For suspected high-grade transformation or to guide biopsy with prior inconclusive imaging	with accelerated CLL or to guide biopsy with prior inconclusive imaging (includes negative CT with rising tumor markers or if conventional imaging documents mets, IF clearly considering resection)

LYMPHOMA (Non-Hodgkins and Hodgkins)	Indicated (can consider <u>PET/MR**</u>)	Indicated (can consider <u>PET/MR**</u>)
MELANOMA (See Uveal melanoma below for indications)	only stage III, IV indicated	only stage III, IV indicated
MERKEL CELL	Indicated	Indicated
MESOTHELIOMA (malignant)		
● Pleural	Indicated only prior to surgery for stage I-III A	Indicated only prior to surgery for stage I-III A
● Peritoneal	Indicated	Indicated
MULTIPLE MYELOMA		
● Smoldering myeloma (asymptomatic)	Indicated	Indicated annually or possibly more frequently as clinically indicated (labs and/or symptoms to suggest progression)
● Active myeloma	Indicated	Indicated
● Plasmacytoma	Indicated	Indicated
NEUROBLASTOMA	Indicated when MIBG is negative, inconclusive, or there are discordant findings between MIBG and pathology	Indicated when FDG PET was used for initial staging or if MIBG has become inconclusive or discordant
NEUROENDOCRINE TUMORS (NET) WHEN UNDIFFERENTIATED/DE-DIFFERENTIATED (including pheochromocytoma, paraganglioma, extrapulmonary large/small cell)	Indicated if used after prior negative or inconclusive Ga68 Dotatate scan	Indicated when FDG was used for initial staging, or when used after prior negative/inconclusive Ga68 Dotatate scan (or MIBG scan) OR after inconclusive conventional imaging

OVARIAN

with prior inconclusive imaging

with prior inconclusive imaging

OCCULT PRIMARY

with prior inconclusive imaging appropriate to pathology of the biopsy that identified the occult malignancy

with prior inconclusive imaging

OSTEOSARCOMA

• Osseous

~~For patients >30 years old:
Indicated when the prior bone scan is inconclusive or negative (i.e., the primary bone tumor is not seen on bone scan). PET can be approved in conjunction with MR of primary site~~

~~For patients >30 yrs old:
Indicated when disease is positive on prior FDG-PET or when there is inconclusive conventional imaging. PET can be approved in conjunction with MR of primary site~~

~~For patients <30 years old:
Indicated
PET can be approved in conjunction with MR of primary site~~

~~For patients <30 years old:
Indicated
PET can be approved in conjunction with MR of primary site~~

PANCREATIC

~~With prior inconclusive imaging OR with any of the following high-risk features:~~

- ~~• borderline resectable disease~~
- ~~• markedly elevated CA19-9 >180 U/ml~~
- ~~• large primary tumor/lymph nodes~~
- ~~• very symptomatic (jaundice, symptomatic gastric outlet obstruction, venous thromboembolism, extreme pain and excessive weight loss)~~

~~When PET was used for initial staging and need to assess response to treatment in order to determine if now a surgical candidate~~

PENILE	with prior inconclusive imaging	with prior inconclusive imaging
PERITONEAL CANCER (PRIMARY)	with prior inconclusive imaging	with prior inconclusive imaging
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)	Indicated when the diagnosis is made OR if suspected based on abnormal PE, abnormal imaging or abnormal labs (i.e., significantly elevated or rising viral titers)	Indicated
PROSTATE (FDG PET only) *See other PET tracer section below for prostate cancer*	Not Indicated	Not Indicated
RENAL	ONLY when conventional imaging is equivocal for metastatic disease and if present would alter initial treatment plan	ONLY when conventional imaging is clearly insufficient in these circumstances: <ul style="list-style-type: none"> • For suspected recurrence/metastatic disease outside of the urinary tract • To monitor treatment with a Tyrosine Kinase Inhibitor (such as sunitinib, sorafenib) for advanced RCC when disease was only seen previously on PET
SKIN SQUAMOUS CELL	with prior inconclusive imaging	Not Indicated
SMALL BOWEL CARCINOMA	Not indicated	with prior inconclusive imaging

~~SOFT TISSUE SARCOMA~~
~~(including soft~~
~~tissue/extraosseous Ewing~~
~~sarcoma and soft~~
~~tissue/extraosseous~~
~~osteosarcoma)/ GIST/~~
~~Rhabdomyosarcoma~~

~~For patients >30 years old: with~~
~~prior inconclusive imaging~~

~~For patients >30 yrs old with~~
~~prior inconclusive imaging~~

~~For patients <30 years old:~~
~~Indicated (does not require~~
~~inconclusive conventional~~
~~imaging)~~

~~For patients <30 yrs old:~~
~~Indicated (does not require~~
~~inconclusive conventional~~
~~imaging)~~

TESTICULAR

●—Seminoma

Not Indicated

~~with prior inconclusive imaging~~
~~OR residual mass >3cm with~~
~~normal AFP and beta-hcG and 6~~
~~weeks post chemotherapy~~
~~(If this final PET/CT is equivocal~~
~~or borderline for residual~~
~~disease, an additional repeat~~
~~PET/CT > 6 weeks later may help~~
~~identify those that can be safely~~
~~observed without additional~~
~~surgery)~~

●—Non-Seminoma

Not Indicated

Not Indicated

THYMOMA/THYMIC CANCER

Indicated

Indicated

THYROID

●—Papillary, Follicular

Not Indicated

~~Indicated with the following 3~~
~~criteria:~~

- ~~●—A thyroidectomy and~~
~~radioiodine ablation were~~
~~done initially; AND~~
- ~~●—Serum thyroglobulin (Tg) is~~
~~>2 ng/ml (unstimulated or~~
~~stimulated) OR there is a~~
~~high anti-thyroglobulin~~
~~antibody (anti-Tg Ab) >1~~
~~year after treatment AND~~
- ~~●—A Negative current I-131/I-~~
~~123 scan OR a Negative~~

		prior stimulated whole body I-131/I-123 scan done at Tg level similar to the current Tg level (a current scan is needed if on radioiodine sensitizing medications)
● Hurthle	If Tg is high and/or pathology is high-risk	If Tg is high and/or pathology is high-risk
● Anaplastic	With prior inconclusive imaging	With prior inconclusive imaging
● Medullary	Not Indicated (see NET/Dotatate indications below)	With prior inconclusive imaging when calcitonin levels ≥ 150 pg/ml or CEA levels >5 ng/ml post-surgery with prior insufficient Dotatate scan
UTERINE	with prior inconclusive imaging	with prior inconclusive imaging
UVEAL MELANOMA	Not Indicated	with prior inconclusive imaging
VAGINAL	Indicated	Indicated
VULVAR	$\geq T2$ or after prior inconclusive imaging	Indicated

MISCELLANEOUS (NON-ONCOLOGIC) INDICATIONS FOR FDG-PET (excluding brain and cardiac PET which have separate Guidelines)

TYPE	INITIAL STAGING	RESTAGING
CASTLEMAN'S DISEASE	Indicated	Indicated

MISCELLANEOUS (NON-ONCOLOGIC) INDICATIONS FOR FDG PET

(excluding brain and cardiac PET which have separate Guidelines)

TYPE	INITIAL STAGING	RESTAGING
HISTIOCYTIC NEOPLASMS:		
• Langerhan's	Indicated	Indicated if on active treatment for multiple bone disease, high risk bone disease or multisystem involvement
• Erdheim-Chester	Indicated	Indicated if on active treatment
• Rosai-Dorfman	Indicated	Indicated if on active treatment

*SARCOIDOSIS

- ~~ONLY if conventional testing (CXR, CT and inflammatory serology) remain inconclusive for known sarcoid to determine:~~
 - ◉ ~~if treatment might be helpful~~
 - ◉ ~~extent of disease, if it will potentially change management~~
 - ◉ ~~response to treatment~~
- ~~OR if strongly suspected sarcoid to determine most suitable site to biopsy~~

*VASCULITIS

- ~~In limited circumstances, with known vasculitis, AFTER conventional imaging (MRA/CTA/MR/CT) has clearly been shown to be insufficient to determine treatment~~

*Adjudications should occur on a case-by-case basis

NON-FDG PET TRACERS

GA68-DOTATATE, GA68-DOTATOC and CU64-DOTATATE FOR NET (Neuroendocrine Tumors)

CANCER TYPE	INITIAL STAGING	RESTAGING
CARCINOID	• Indicated	• Indicated

~~GA68-DOTATATE, GA68-DOTATOC and CU64-DOTATATE FOR NET (Neuroendocrine Tumors)~~

CANCER TYPE	INITIAL STAGING	RESTAGING
EXTRAPULMONARY LARGE AND SMALL CELL MEN-1/MEN-2 SYNDOMES NEUROENDOCRINE TUMORS (NET) PHEOCHROMOCYTOMA PARAGANGLIOMA	• <u>PET/MR^{††}</u> can be considered	• <u>PET/MR^{††}</u> can be considered
MEDULLARY THYROID	Prior CT/ MRI insufficient to <ul style="list-style-type: none"> • Determine extent of treatment plan • Determine if candidate for invasive diagnostic/ therapeutic procedure • Determine optimal anatomic location for invasive procedure 	When calcitonin levels ≥ 150 pg/ml or CEA levels >5 ng/ml post-surgery

~~YTTRIUM 90 (Y90)~~

~~**Y90 PET SCAN:** Indicated when performed immediately after treatment of liver malignancy (primary or metastatic) with Y90 (usually within 24 hours while Y90 is still detectible). The Y90 treatment is the tracer for this PET (see Y90 background section).~~

~~PSMA TRACERS (such as F18 piflufolastat (Pylarify®), GA 68 PSMA 11, GA 68 gozetotide (Locametz®), and GA 68 gozetotide (Ilucix®)); F18 FLUCICLOVINE (AXUMIN®) and C11 CHOLINE~~
For PROSTATE CANCER

CANCER	INITIAL STAGING	RESTAGING
PROSTATE (PET/CT or PET/MRI ^{††}) <ul style="list-style-type: none"> After a negative Axumin® PET, a subsequent PSMA PET is not covered until a repeat PSA (done at least 3 months later) shows a progressive rise 11-Choline should be approved only if PSMA and/or Axumin® are not available. Order of preference typically would be PSMA, then Axumin®, then 11-Choline 	<p>Only PSMA (not Axumin® or Choline) is indicated in initial staging for high risk; defined as 1 or more of the following:</p> <ul style="list-style-type: none"> Gleason 8, 9 or 10 (specimen contains pattern 4 or 5) Gleason 7 IF primary pattern** is 4 (4+3=7) Gleason 7 primary pattern 3 (3+4=7) must ALSO have a PSA >10 and/or cT2b-cT3c disease Gleason 6 disease (3+3=6) must ALSO have a PSA >20 and/or cT3a-cT4 disease >50% cores positive for cancer in random biopsy <p>**The Primary Pattern refers to the 1st number in the Gleason Pattern</p> <p>Pelvic MRI can be approved concurrently if needed for surgical planning</p>	<p>For post-surgery/radiation in suspected recurrence with at least two separate detectable PSA levels above the nadir for that patient for:</p> <ul style="list-style-type: none"> Axumin® (or Choline) <ul style="list-style-type: none"> Indicated if bone scan and CT/MRI are negative or inconclusive PSMA (preferred tracer) <ul style="list-style-type: none"> PSA < 10 Indicated PSA > 10 Indicated if bone scan and CT/MRI are negative or inconclusive <p>For post-surgery/radiation in known recurrence, PSMA is approvable if:</p> <ul style="list-style-type: none"> Disease was previously seen only on PSMA PET <p>For metastatic castrate resistant disease that have failed both taxanes and ARDI, PSMA is approvable if:</p> <ul style="list-style-type: none"> Individual is a candidate for Lu-PSMA treatment (Pluvicto®) (must be

clearly documented in
note)

- Restaging on Lu-PSMA
treatment (Pluvicto®)

BACKGROUND

Inconclusive Imaging includes the following:

- Equivocal or ambiguous other prior standard imaging if results will change management
- Biopsy guidance (e.g., tumors with necrosis)
- High suspicion of metastases due to clinical or histopathological or laboratory considerations but with no evidence of metastases on standard initial staging
- Clinical or laboratory disease progression with negative standard imaging
- Contraindications to IV contrast, including allergy and chronic renal failure precluding MRI in a patient with a known or highly suspected malignancy
 - PET/CT may be indicated if CT cannot be performed due to significant iodinated contrast allergy or chronic renal failure **AND** MRI cannot be performed due to significant gadolinium contrast allergy or if renal failure with $GFR < 30$.²
- Evaluation for other distant metastases prior to surgical resection of limited metastases/local disease and otherwise negative prior standard imaging
- Response to neoadjuvant therapy when CT/MR insufficient
- Residual masses after completion of therapy
- Target definition for radiation planning
- If previous conventional imaging has been inconclusive, and it seems reasonable to expect that to still be the case, new conventional imaging is NOT required

In situations where there is questionable disease in an area that requires significantly invasive procedures to obtain tissue (such as open surgical procedures), and malignancy is high on the radiographic differential diagnosis, it is reasonable and medically appropriate to attempt to gain as much information about diagnosis from imaging prior to subjecting the patient to tissue diagnosis that has real risk of morbidity/mortality.

Definition of Disease Progression:

For any signs of progression, as noted below, that could not be confirmed by other imaging, PET/CT is needed. Findings concerning for progression of disease include:

- Worsening of symptoms such as pain or dyspnea
- Evidence of worsening or new disease on physical examination
- Declining performance status
- Unexplained weight loss
- Increasing alkaline phosphatase, alanine aminotransferase (ALT), aspartate transaminase (AST), or bilirubin
- Hypercalcemia
- New radiographic abnormality or increase in the size of pre-existing radiographic abnormality
- New areas of abnormality on functional imaging (e.g., bone scan, PET/CT)
- Increasing tumor markers (e.g., carcinoembryonic antigen [CEA], CA 15-3, CA27.29)
- To help differentiate possible recurrent/active tumor from necrotic or inactive scar tissue, malignant from benign tissue, and nondescript benign changes.

PET and separate CT/MR: Positron emission tomography-Computed Tomography (PET/CT) is a rapidly developing and changing technology that is able to detect biochemical reactions, e.g., metabolism, or abnormal distribution of cell receptors within body tissues. A radioactive tracer is used during the procedure. Unlike other nuclear medicine examinations, PET/CT can measure metabolic activity of the cells of body tissues, providing information about the functionality and structure of the particular organ or tissue examined. PET/CT may also detect biochemical changes that help to evaluate malignant tumors and other lesions.

TYPICALLY, separate CT/MR scans being requested concurrently with a PET are not needed. There should be very few instances where separate studies are needed, and when this does happen, it is usually SITE SPECIFIC. Most PET scanners now in use can “simultaneously” perform PET and CT (whether for CT Attenuation or a Diagnostic CT). Contrast can be given for the CT portion of the PET/CT. A separate request for diagnostic CTs in addition to PET is, therefore, not needed. The ordering MDO can specify to the imaging provider details about what type of CT scan is desired to be done with the PET portion. “Exceptions” generally occur when CT is needed in a plane other than standard axial imaging (for example: coronal CT for facial bone imaging that might be needed for surgical reconstruction). Separate MRIs are likewise rarely needed, but are perhaps somewhat more frequently needed than additional, separate CTs,

~~since MRI does allow multiple imaging planes and may provide additional information. When evaluating for these “exceptions”, the reason additional separate imaging is needed should be clearly delineated before approval.~~

~~–[†]**PET/MR:** Patients with certain malignancies may benefit from PET/MRI since it detects brain and liver metastases better when compared with PET/CT. NCCN does suggest consideration of PET/MR in some malignancies, but not specifically for replacing PET/CT. PET/MRI should only be considered for those specific malignancies (see table for specific cancers) and in certain situations. Typically, PET/CT should suffice; however, under some circumstances, with clear explanation of why PET/MR is preferred rather than PET/CT, PET/MR may be an appropriate study.~~

Langerhans Cell Histiocytosis is the most common type of histiocytosis, with variable presentations and sites involvement. Some studies suggest PET/CT may be more effective in detecting bone lesions compared with MRI and bone scans in assessing disease response as healing/treatment changes of bone lesions on conventional imaging may be delayed. However, PET/CT is not the modality of choice in assessing disease response of lung or brain lesions.

Y90 PET Scans:

~~Hepatic radioembolization, involving intraarterial injection of yttrium-90 (Y90)-labeled glass or resin microspheres, is used for liver-dominant malignancy or metastases that are unresectable. A Tc99m MAA nuclear scan (typically requiring SPECT) is performed before the actual treatment with Y90. MAA, which is similar in size to the Y90 microspheres, mimics the distribution of the Y90 particles and should embolize within the tumor’s hepatic arterioles, thus outlining the expected localization of the radiation. The scan is compared to a CTA/MRA to evaluate for any possible shunting of the treatment agent to the lungs or the GI tract. Coils can be placed as needed to minimize any shunting of Y90 to areas other than the desired target.~~

~~**Post-procedure imaging (within 24 hours)** with either SPECT or PET (at the discretion of the treating physicians) is then performed to confirm the final distribution of the Y90 and to calculate the actual radiation dose delivered to the tumor. Utilizing the Bremsstrahlung radiation of the Y90 embolization agent, SPECT (or SPECT/CT) can be completed with routine nuclear medicine collimators. However, due to their higher energy level (as compared to routine nuclear medicine agents), the Y90 photons scatter and/or pass through the collimator septa and degrade the image quality. Alternatively, **PET scanning can be done, again using the Y90 treatment agent itself**, but for PET via a minor decay pattern that emits a positron (32 in every one million decays) that is detectable with PET scanners.~~

~~**FDG PET** may be needed later (ideally performed >12 weeks after treatment) to assess tumor response to this radiation, in accordance with the tumor-specific guidelines for FDG PET~~

~~restaging (in the table above) and may still require inconclusive conventional imaging, if necessary for the type of cancer being treated.~~

Lung Cancer – Small Cell: Initial Staging is classified as Limited Stage (LS) and Extensive Stage (ES). In limited stage disease, the disease burden is localized to the chest (Any T, Any N, M0) AND able to be encompassed in a tolerable radiation plan. Patients with disease OUTSIDE of the chest (M1) or T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan are classified as extensive stage. When a patient cannot clearly be classified as ES but there are findings on imaging suggestive of disease (typically extra-thoracic findings such as a liver lesion), then PET may be used to help classify the extent of disease as ES or LS. If conventional imaging clearly shows ES disease, then PET is not indicated. Restaging: When radiation is planned (either for LS disease OR for ES disease that has responded to treatment), PET is indicated to determine radiation fields. Otherwise, disease reassessment/response to therapy is with conventional imaging⁶⁴.

Melanoma: Local satellite/in-transit recurrences are in the deep dermis or subcutaneous fat within or adjacent to the melanoma scar. They are recurrences that occur after an initial adequate wide excision, likely represent dermal lymphatic disease and do need imaging at diagnosis. Persistent disease, by contrast, is disease remaining in the melanoma scar after an initial resection (likely due to inadequate resection) and imaging would only be indicated if stage III or IV disease is present³³.

Mesothelioma^{36, 65}: The evaluation of recurrent pleural effusion and/or pleural thickening includes CT chest, thoracentesis and pleural biopsy. The diagnostic sensitivity of this investigation is 70-75%. If the first biopsy is non-diagnostic, there is a higher chance that subsequent biopsies will be non-diagnostic, thus a PET to guide subsequent biopsy is reasonable in this situation.

Multiple Myeloma: Making the diagnosis of myeloma is complex and may include bone marrow biopsy, cytometry, imaging etc. However, once the diagnosis of myeloma (multiple myeloma or plasmacytoma) is confirmed, PET may be considered.

Neuroendocrine Tumors (NET)⁵⁷: a Somatostatin Receptor (SSTR) analog PET (commonly dotatate) is indicated at initial diagnosis to evaluate for metastatic disease. If a moderately invasive procedure is needed to confirm the diagnosis (i.e. open surgery), PET prior to this open biopsy may be reasonable when the clinical picture, labs and imaging are consistent with a NET. Restaging can be done with conventional imaging (CT/MRI). However, if progression is seen and/or SSTR directed therapy is being considered, then SSTR-PET is indicated. Because liver lesions are often not well imaged on SSTR-PET, a dedicated liver MRI at the time of SSTR-PET may be indicated if there are known or suspected liver metastases.

FDG PET may be more useful when a NET is metabolically active, such as in poorly differentiated NET and well differentiated grade 3 NET with a high Ki67 ($\geq 55\%$). For poorly

differentiated NET, indeterminate conventional imaging is needed prior to FDG PET. For well-differentiated grade 3 NET with a high Ki-67 ($\geq 55\%$), a negative dotatate PET is required before an FDG PET can be considered.

Neurofibromatosis type 1 (NF1): Surveillance of lesions is completed with MRI (often whole body MRI.) Approximately 5% of patients with neurofibromatosis are thought to develop soft tissue sarcomas, most commonly malignant peripheral nerve sheath tumors (MPNSTs), a type of sarcoma. Risk factors for MPNST transformation include: whole *NF1* gene deletion, family history of MPNST, prior radiation therapy, large plexiform neurofibroma burden or multiple distinct nodular lesions on magnetic resonance imaging (MRI), neurofibromatous neuropathy, and atypical neurofibroma(s). Once a PET has been done and was negative, rapid growth on conventional imaging and plan for biopsy need to be provided prior to consideration of another PET.

Occult Primary: The typical evaluation for a suspected metastatic malignancy includes a thorough physical exam, laboratory evaluation, CT of the Chest, Abdomen and Pelvis AND a biopsy of the site of disease. The biopsy results then indicate either a clear primary for which the relevant guideline is applied or an epithelial cancer (not site specific). Epithelial cancers are further classified as adenocarcinoma, carcinoma not specified, squamous cell carcinoma (SCC) or neuroendocrine carcinoma (see NET in guideline). If the primary is still not identified, further guidance is often complex and based on the site of disease identified.

Pheochromocytoma and Paraganglioma: Hypertension, tachycardia, sweating and syncope are typical symptoms. Biochemical workup includes catecholamines (such as metanephrines, normetanephrine, and/or dopamine). Elevations in catecholamines that are greater than two times above the upper limit of normal are usually present. Biopsy of a pheochromocytoma and paraganglioma that is biochemically active is contraindicated. Thus, when the clinical picture AND labs is consistent with pheochromocytoma/paraganglioma, the SSTR-PET can be approved without biopsy confirmation. However, if the catecholamines are not elevated (as above), in the setting of clinical concern and a mass, biopsy is required.

Prostate Cancer Initial Staging: PSMA is the only approvable tracer for initial staging. Risk groups are determined by the Gleason Score (on pathology report), PSA, clinical stage (by exam (digital rectal exam (DRE) and/or imaging such as pelvis MRI). This information may also be expressed as a grade group. The three risk groups for which PSMA PET is indicated are: very high risk, high risk and unfavorable intermediate risk. Any of the following criteria place the patient into one of these risk groups and PSMA PET may be approved for initial staging:

- Gleason score 8, 9 or 10
- Primary pattern 4 (Gleason 4+3=7)
- PSA > 20 AND Gleason score 3+3=6 or higher
- PSA > 10 AND Gleason score 3+4=7

- PSA > 10 AND Gleason score 3+3=6 AND clinical stage ≥ T2b
- Clinical stage ≥ T3a AND Gleason score 3+3=6 or higher
- Clinical stage ≥ T2b AND Gleason score 3+4=7 or higher
- ≥ 50% of cores positive for cancer in a random, non-targeted prostate biopsy
- Grade group 3, 4 or 5 disease

When active surveillance was selected as the initial plan of care, PSMA PET is indicated when the disease progresses to very high risk, high risk or unfavorable intermediate risk using the most recent Gleason score/biopsy result, clinical stage and PSA level.

A biopsy typically needs to be done confirming the diagnosis of prostate cancer prior to PSMA PET. If the PSA is > 50, when there is no clinical concern for infection nor has there been recent instrumentation AND there is an intent to treat the patient for prostate cancer without biopsy confirmation, PSMA PET can be considered. Situations where this may be reasonable are when the biopsy poses significant risk (i.e., anticoagulation or significant comorbidity) OR if treatment is urgently needed (such as spinal cord compromise from metastases)⁶⁶.

Patients who are metastatic at diagnosis (no prior treatment) are staged with conventional imaging². PSMA PET can be considered if there are indeterminate findings on conventional imaging and specific details regarding how clarification of these findings with PSMA PET would change treatment are provided.

Prostate Cancer Restaging: PSMA is the preferred tracer for restaging of prostate cancer due to the increased sensitivity and specificity for detection of disease. There may be situations where Axumin or Choline are approvable tracers such as for detection of inconclusive findings on bone scan, when prior PET scans have used that tracer and direct comparison is needed or if PSMA is not available. For both Axumin and Choline, inconclusive conventional imaging is required and the reason that tracer is being requested instead of PSMA needs to be provided. When a PSMA PET has failed to detect a site of recurrence (i.e. PSMA PET was negative previously yet PSA continues to rise), a repeat PSMA PET may be approved as early as 6 months if the PSA doubling time is < 12 months.

Thyroid Cancer: Thyroid cancer can be grouped into three main histologic subtypes: Differentiated (including papillary, follicular, and oncocytic), Anaplastic and Medullary.

Differentiated thyroid cancer: As iodine is taken up by differentiated thyroid cancers, an iodine scan (I-123 and/or I-131) is often the first line imaging modality (in addition to ultrasound). When there is a discordance between the tumor marker (thyroglobulin or thyroglobulin antibody) and imaging (I-123 or I-131 scan) AND the thyroid tissue has been removed (total or completion thyroidectomy) or ablated, this indicates that the tumor may have de-differentiated and FDG PET is indicated. After therapy with I-131 it can take several months for Tg to disappear from the circulation, so an early elevated level does not

necessarily indicate a recurrence/persistence of the cancer. For papillary, follicular and oncocytic thyroid cancer, FDG PET can be approved for the following:

- A total (or completion) thyroidectomy OR radioiodine iodine has been completed; AND
- Serum thyroglobulin (Tg) is >2 ng/ml (unstimulated or stimulated) OR there is a high anti-thyroglobulin antibody (anti-Tg Ab) >1 year after treatment AND
- A Negative current I-123 (or I-131) scan OR a Negative prior stimulated whole body I-123 (or I-131) scan done at Tg level similar to the current Tg level (a current scan is needed if on radioiodine sensitizing medications)

Anaplastic thyroid cancers are aggressive and imaging with FDG PET is appropriate.

Medullary thyroid cancers arise from the neuroendocrine parafollicular C cells of the thyroid and are not iodine-avid. Staging with SSTR PET is indicated for initial staging when indeterminate imaging is provided. For restaging, when calcitonin level is ≥ 150 pg/ml or CEA levels >5 ng/ml post-surgery AND indeterminate imaging (including negative CT/MRI with elevated calcitonin and/or CEA) is provided, PET is indicated. Typically the tracer for restaging is SSTR (dotatate), however, there may be situations where an FDG PET is reasonable.

REFERENCES

1. NCCN Imaging Appropriate Use Criteria™. National Comprehensive Cancer Network (NCCN). Accessed January 31, 2023.
<https://www.nccn.org/professionals/imaging/default.aspx>
2. W. L, R. D, D.F. J, al. e. Updates to advanced prostate cancer: AUA/SUO guideline (2023).
Journal of Urology. 2023;209(6)doi:10.1097/JU.0000000000003452
3. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer Version 3.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 13, 2023. Accessed April 23, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
4. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Neuroendocrine and Adrenal Tumors Version 2.2022. National Comprehensive Cancer Network®. May 8, 2023. Updated December 21, 2022. Accessed April 12, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
5. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kaposi Sarcoma Version 1.2023. National Comprehensive Cancer Network®. Updated December 20, 2022. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/kaposi.pdf
6. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Pediatric Acute Lymphoblastic Leukemia Version 2.2023. National Comprehensive Cancer Network®. Updated March 10, 2023. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf
7. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia Version 1.2022. National Comprehensive Cancer Network®. May 8, 2023. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
8. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 3.2023. National Comprehensive Cancer Network®. May 8, 2023. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
9. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Anal Carcinoma Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 18, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf
10. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Basal Cell Skin Cancer Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 10, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf
11. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Biliary Tract Cancers Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 10, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf

12. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
13. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bone Cancer Version 3.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 4, 2023. Accessed April 13, 2023. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
14. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 4.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 23, 2023. Accessed April 14, 2023. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
15. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Cervical Cancer Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
16. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 25, 2023. Accessed April 12, 2023. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
17. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Rectal Cancer Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 25, 2023. Accessed May 8, 2023. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
18. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine Neoplasms Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 28, 2023. Accessed April 2023, 2023. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
19. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 10, 2023. Accessed April 12, 2023. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
20. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastric Cancer Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 10, 2023. Accessed April 12, 2023. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
21. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gestational Trophoblastic Neoplasia Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated December 20, 2022. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf
22. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastrointestinal Stromal Tumors Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 13, 2023. Accessed April 13, 2023. https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf

23. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated December 20, 2022. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
24. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hepatocellular Carcinoma Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 10, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf
25. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer Version 3.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 13, 2023. Accessed April 11, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
26. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated January 25, 2023. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
27. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) T-Cell Lymphomas Version 1.2023. May 8, 2023. Updated January 5, 2023. Accessed April 13, 2023. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf
28. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Primary Cutaneous Lymphomas Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated January 5, 2023. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf
29. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Pediatric Hodgkin Lymphoma Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated March 9, 2023. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/ped_hodgkin.pdf
30. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Pediatric Aggressive Mature B-Cell Lymphomas Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 4, 2023. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/ped_b-cell.pdf
31. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hodgkin Lymphoma Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated November 8, 2022. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
32. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) B-Cell Lymphomas Version 2.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated February 8, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
33. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma: Cutaneous Version 2.2023. National Comprehensive Cancer Network®. May 8,

2023. Updated March 10, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

34. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma: Uveal Version 1.2023. National Comprehensive Cancer Network®. May 10, 2023. Updated May 4, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf

35. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Merkel Cell Carcinoma Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated April 10, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf

36. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Mesothelioma: Pleural Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated December 15, 2022. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf

37. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Mesothelioma: Peritoneal Version 1.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated December 15, 2023. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/meso_peritoneal.pdf

38. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma Version 3.2023. National Comprehensive Cancer Network®. May 8, 2023. Updated December 8, 2022. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

39. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Neuroendocrine and Adrenal Tumors Version 2.2022. National Comprehensive Cancer Network®. May 8, 2023. Updated December 21, 2022. Accessed April 18, 2023
https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

40. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated December 22, 2022. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

41. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Occult Primary (Cancer of Unknown Primary [CUP]) Version 3.2023. National Comprehensive Cancer Network®. May 9, 2023. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf

42. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Penile Cancer Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated December 1, 2022. Accessed April 13, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf

43. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer Version 4.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated

January 18, 2023. Accessed April 11, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

44. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Squamous Cell Skin Cancer Version 1.2023

National Comprehensive Cancer Network®. May 9, 2023. Updated March 10, 2023. Accessed April 13, 2023. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf

45. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Small Bowel Adenocarcinoma Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated January 9, 2023. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf

46. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft Tissue Sarcoma Version 2.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated April 25, 2023. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf

47. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Testicular Cancer Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated January 26, 2023. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf

48. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Thymomas and Thymic Carcinomas Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated December 15, 2022. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf

49. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Thyroid Carcinoma Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated March 24, 2023. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

50. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine Neoplasms Version 2.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated April 28, 2023. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

51. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Vulvar Cancer Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated December 22, 2022. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf

52. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Histiocytic Neoplasms Version 1.2022. National Comprehensive Cancer Network®. May 9, 2023. Updated May 20, 2022. Accessed April 13, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

53. Reilly KM, Kim A, Blakely J, et al. Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. *J Natl Cancer Inst.* Aug 1 2017;109(8)doi:10.1093/jnci/djx124

54. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central Nervous System Cancers Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated March 24, 2023. Accessed April 14, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
55. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft Tissue Sarcoma Version 2.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated April 25, 2023. Accessed April 14, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
56. Chinnery PF. Neuroferritinopathy. In: M.P. A, M. MG, R.A. P, al. e, eds. *GeneReviews®*. University of Washington, Seattle; 2005.
57. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Neuroendocrine and Adrenal Tumors Version 2.2022. National Comprehensive Cancer Network®. May 9, 2023. Updated December 21, 2022. Accessed April 18, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
58. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer Version 1.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated September 16, 2022. Accessed April 11, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
59. Positron Emission Tomography (PET) scans for lymphoma. Washington State Health Care Authority. Updated January 18, 2019. Accessed January 31, 2023,
<https://www.hca.wa.gov/assets/program/PET-scans-lymphoma-final-findings-decision-20190118.pdf>
60. About the Health Care Authority (HCA). Washington State Health Care Authority. Accessed January 31, 2023. <http://hca.wa.gov/about-hca>
61. Lewin J, Sayers L, Kee D, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. *Annals of Oncology*. 2018;07/01/ 2018;29(7):1569-1574. doi:<https://doi.org/10.1093/annonc/mdy124>
62. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *The Lancet Oncology*. 2016;17(8):e328-e346. doi:10.1016/S1470-2045(16)30206-6
63. Foundation IM. What is Relapse in Myeloma? International Myeloma Foundation. May 9, 2023. Accessed April 21, 2023. <https://www.myeloma.org/treatment/relapse-definition>
64. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Small Cell Lung Cancer Version 3.2023. National Comprehensive Cancer Network®. May 9, 2023. Updated December 21, 2022. Accessed April 11, 2023.
https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
65. de Fonseca D, Underwood W, Staddon L, et al. Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial). *BMJ Open Respir Res*. 2018;5(1):e000270. doi:10.1136/bmjresp-2017-000270

66. [Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. *J Urol.* Apr 25 2023;101097ju00000000000003492. doi:10.1097/ju.00000000000003492](#)

POLICY HISTORY

Date	Summary
<u>May 2023</u>	<ul style="list-style-type: none"> • Reorganized: <ul style="list-style-type: none"> ○ <u>Cancers where the guidance is straightforward into a list for ICRs and non-PET PCR's can approve/deny</u> ○ <u>Definitions to background</u> • Revised indeterminate imaging and contraindications to conventional imaging sections • Updated: <ul style="list-style-type: none"> ○ <u>Surveillance PET section with additional guidance</u> ○ <u>Following Cancers to be consistent with updated version of NCCN</u> <ul style="list-style-type: none"> ▪ <u>Adrenal: added indications in limited circumstances</u> ▪ <u>Breast: changed to requiring inconclusive imaging and added a restaging indication for FES PET in special tracer section</u> ▪ <u>Colorectal: added liver directed therapy and potentially curable M1 disease to restaging</u> ▪ <u>Esophageal: initial staging clarified as indicated for non-metastatic, restaging changed from indicated to following chemoradiation or with indeterminate imaging</u> ▪ <u>Small cell lung cancer: clarified staging in background section, limited stage: changed restaging to prior to radiation or with indeterminate imaging; for extensive stage: added indication for indeterminate imaging in initial staging, added indication when radiation is planned for restaging</u> ▪ <u>Melanoma: added indication for satellite/in-transit and dermal melanomas that lack epidermal involvement</u> ▪ <u>Neuroendocrine: separated types of NET, changed wording for poorly differentiated and well differentiated high grade in FDG section; added detail re what is needed for restaging in SSTR section</u> ▪ <u>Renal: changed to not indicated</u> ▪ <u>Skin squamous cell: added indication for biopsy proven lymph node positive and metastatic disease</u> ▪ <u>Sarcoma: separated rhabdomyosarcoma as indicated (remainder require inconclusive imaging if > 30 yo)</u> ▪ <u>Thyroid: moved most of detail into background section, made indications consistent with current NCCN guidance</u> ▪ <u>MPNST: Added indication in section for NF1</u>

	<ul style="list-style-type: none"> ▪ <u>Prostate cancer: Moved detail for initial staging and non-PSMA tracers into background; updated restaging indications</u> • <u>Regrouped the following Cancers in the table to coincide with grouping in NCCN:</u> <ul style="list-style-type: none"> ○ <u>Biliary Tract</u> ○ <u>Bone Cancers</u> ○ <u>Uterine Cancers</u> • <u>Added TNM explanation and cancer-specific background sections when needed for additional</u> <ul style="list-style-type: none"> • <u>General information moved to the beginning of the guideline with added statement on clinical indications not addressed in this guideline</u>
May 2022	<ul style="list-style-type: none"> • Updated changes based on NCCN including updates most notably for prostate cancer, Hurthle, NETs • Clarified when PET may be approved prior to biopsy for lung nodules and when PET is unnecessary (e.g., disease clearly present in both sides of chest and/or outside the chest) • Added indications for rare specific histiocytic syndromes and for sarcoid and vasculitis for non-oncological indications • Added restaging for RCC and pancreatic cancer in specific situations • Added indications for Y90 PET scan (liver malignancy) • Updated definitions of clinical guidelines (PET, PET/CT, and PET with CT Attenuation) • Minor wording clarifications, table adjustments
June 2021	<p>Added:</p> <ul style="list-style-type: none"> • Definitions • CART T info • PTLT information added • PET/MRI information • Updated/added details for Prostate cancer and PSMA, Axumin and Choline • Minor adjustments to the PET FDG table, such as added details from NCCN, clarifications, separation of non-malignant uses
May 2020	<ul style="list-style-type: none"> • Modified to table format • Added section of follow up of a new or interval growth of a mixed pulmonary lung nodule on subsequent LDCT (NCCN 2020) • Initial staging indicated

	<ul style="list-style-type: none"> ○ Changed AML to extramedullary disease (previously lymphomatous involvement) ○ Changed Breast cancer stage IIb and above (previously III and IV) ○ Added Castleman's disease ○ Added for Chronic Lymphocytic Leukemia to guide biopsy ○ Changed Mesothelioma to only prior to surgery for stage I-III A ○ Added "soft tissue" sarcoma in pediatric patient ○ Added Thymoma and thymic cancer ○ Added Langerhans Cell Histiocytosis predominantly osseous disease (previously not included) ● Initial staging which is only indicated after prior inconclusive imaging (NCCN 2019/2020) <ul style="list-style-type: none"> ○ Added AIDS related Kaposi sarcoma ○ Changed Anal carcinoma (previously indicated) ○ Added Ewing sarcoma osseous ○ Added Gestational trophoblastic disease ○ Added Hepatocellular/Intrahepatic Cholangiocarcinoma (previously not included) ○ Added Fallopian tube and primary peritoneal cancer ○ Added Osteosarcoma osseous ○ Changed Penile cancer (previously indicated with palpable nodes) ● Initial staging NOT indicated (NCCN 2019/2020) <ul style="list-style-type: none"> ○ Changed testicular (previously indicated) ○ Added Uveal Melanoma ○ Added Langerhans Cell Histiocytosis predominantly non-osseous disease (previously not included) ● Restaging indicated (NCCN 2019/2020) <ul style="list-style-type: none"> ○ Added Castleman's disease ○ Added for accelerated Chronic Lymphocytic Leukemia and to guide biopsy ○ Added Gastric Cancer post radiation treatment ○ Changed Mesothelioma to only prior to surgery for stage I-III A ○ Added "soft tissue" to sarcoma in pediatric patient ○ Added Thymoma and thymic cancer ○ Added Langerhans Cell Histiocytosis predominantly osseous disease (previously not included)
--	--

	<ul style="list-style-type: none"> ● Restaging which are only indicated after prior inconclusive imaging (NCCN 2019/2020) <ul style="list-style-type: none"> ○ Removed for resectable disease in Colorectal cancer ○ Removed for if candidate for surgery/locoregional therapy for endometrial cancer ○ Specified Ewings sarcoma osseous ○ Added Extrahepatic Cholangiocarcinoma (previously not indicated) ○ Added Gallbladder carcinoma (previously not indicated) ○ Changed Gastric Cancer to prior inconclusive imaging or if radiation planning considered (previously indicated if no metastasis or early disease) ○ Added Gestational trophoblastic disease ○ Added Hepatocellular/Intrahepatic Cholangiocarcinoma (previously not included) ○ Changed Ovarian cancer (previously indicated for greater than Stage I) ○ Added Fallopian tube and all stages of primary peritoneal cancer ○ Added Osteosarcoma osseous ○ Added that for pheochromocytoma/ paraganglioma, extrapulmonary large/small cell, restaging FDG PET/CT can be done after inconclusive CT ○ Modified Seminoma with residual mass >3cm or 6 weeks post chemotherapy (previously indicated) ○ Added Uveal melanoma ● Restaging NOT indicated (NCCN 2019/2020) <ul style="list-style-type: none"> ○ Added AIDS related Kaposi sarcoma ○ Changed Testicular non-seminoma (previously indicated) ○ Added Langerhans Cell Histiocytosis predominantly non-osseous disease (previously not included) ● Added CT face/neck may be done in conjunction with PET when surgery or radiation is planned ● Added to head and neck cancer that if a final PET is equivocal or borderline for residual disease PET, a repeat PET/CT at ≥ 6 weeks may help identify those that can be safely observed without additional surgery ● Medullary thyroid: added FDG restaging indicated when CEA >5ng/ml post surgery and after prior insufficient Dotatate scan ● Modified pancreatic cancer symptoms to excessive weight loss ● Added to Seminoma: if final PET is equivocal or borderline for residual disease PET, a repeat PET/CT at ≥ 6 weeks may help
--	---

	<p>identify those that can be safely observed without additional surgery)</p> <ul style="list-style-type: none"> • Thyroid FDG changed serum thyroglobulin level to $>2\text{ ng/ml}$ (previously $>5\text{ ng/ml}$) and added ‘current OR two prior stimulated whole body ^{131}I ^{123}I scans are negative (a current scan is needed if on radioiodine sensitizing medications)’ • Ga^{68} Dotatate added restaging calcitonin levels $\geq 150\text{ pg/ml}$ or CEA levels $>5\text{ ng/ml}$ post surgery • F^{18} Fluciclovine (Axumin) <ul style="list-style-type: none"> ○ Initial staging changed to: With prior inconclusive bone scan with no CT/MRI correlate; or inconclusive bone SPECT/CT ○ Restaging changed to with rising/persistent PSA and after CT/MRI has been performed and is insufficient for detection of metastases • Added Inconclusive imaging features to background as noted in NCCN 2020 • Added Disease progression to Background as noted in NCCN 2020 • Added Section of Langerhans Cell Histiocytosis to background section
September 2019	<ul style="list-style-type: none"> • Removed Introduction section • Removed “Important Note” • Changed title “The following are noncovered for all other indications including (but not limited to):” to “<u>The following are noncovered for F^{18} FDG, Ga^{68} Dotatate, F^{18} Fluciclovine (NCCN 2019):</u>” • Under noncovered for F^{18} FDG, Ga^{68} Dotatate, F^{18} Fluciclovine section, added the following: <ul style="list-style-type: none"> ○ Breast cancer Initial Staging for Stage I and II Breast Cancer ○ Melanoma Initial and Restaging for Stage I and II Melanoma (NCCN 2016) ○ Bladder Cancer non muscle invasive (by imaging or tissue sample) ○ Vulvar Cancer $\leq \text{T2}$ or no suspicion of metastatic disease ○ Prostate Cancer Initial or Restaging ○ Small cell lung cancer Staging (Initial or Restaging) for extensive disease ○ Ovarian Cancer Restaging if stage I ○ Pancreatic Cancer Restaging

	<ul style="list-style-type: none"> ○ Renal Cancer – Initial and Restaging ○ Skin Squamous Cell Carcinoma – Restaging ○ Gastric Cancer – Initial staging if there is evidence of metastases (M1), or very early disease (T1) ○ Malignant Pleural Mesothelioma – Initial staging except if stage I-III A and pre-surgical ○ Hepatocellular / Intrahepatic Cholangiocarcinoma – Initial and Restaging ○ Gallbladder/ Extrahepatic Cholangiocarcinoma – Restaging ○ Small bowel adenocarcinoma – Initial Staging ○ Chordoma – Restaging ○ Adrenal (except pheochromocytoma/ paraganglioma) – Initial or Restaging ○ Smoldering Myeloma – except to discern smoldering from active myeloma with negative skeletal survey ○ ALL (Acute Lymphoblastic Leukemia)/ AML (Acute Myelogenous Leukemia) – Unless prior imaging suggests lymphomatous involvement ○ BCC (Basal Cell Carcinoma (of the skin)) ○ Infection and/or Inflammation: removed “– PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin.” ● Under indications for oncological PET heading, added: “Note: for radiation treatment planning, contact health plan directly” ● Under Initial Treatment Strategy, the first sentence now specifies “active myeloma” instead of “myeloma” previously ● Under Initial Treatment Strategy, the last sentence now replaces “after a” with “AND”: “To determine the optimal anatomic location for an invasive procedure AND prior imaging insufficient” ● “CLL – chronic lymphocytic leukemia (PET/CT is generally not useful in CLL/SLL but may be necessary to direct nodal tissue sampling when high grade histologic transformation is suspected) (NCCN, 2018).” has been changed to “CLL (Chronic Lymphocytic Leukemia): only when high grade histologic transformation is suspected (NCCN, 2018)” ● Changed references for SPN to “(Bueno, 2018; MacMahon, 2017)” from previous “(Vansteenkiste, 2006)” ● Removed the section: <ul style="list-style-type: none"> “Excluding <ul style="list-style-type: none"> ● ALL – acute lymphoblastic leukemia
--	--

	<ul style="list-style-type: none"> ○ Unless prior CT imaging suggest lymphomatous involvement ● AML—acute myelogenous leukemia ○ Unless clinical suspicion for extramedullary disease ● BCC—basal cell carcinoma (of the skin) ● Prostate cancer (NCCN, 2018)” ● Added “EXCEPT for the following, which are only indicated after prior inconclusive imaging (NCCN 2019): <ul style="list-style-type: none"> ○ Colorectal ○ Ovarian/ fallopian ○ Sarcoma/ GIST/ Uterine/Rhabdomyosarcoma ○ Chordoma ○ Muscle invasive bladder cancer ○ Endometrial Cancer ○ Penile (for palpable nodes only) ○ Occult Primary ○ Pancreatic Cancer (unless high risk features: borderline resectable, markedly elevated CA19-9 > 180 U/ml, large primary tumor/ lymph nodes) ○ Skin squamous Cell Carcinoma ○ Gallbladder/ Extrahepatic Cholangiocarcinoma ○ Poorly differentiated neuroendocrine tumors with prior negative Ga68 Dotatate/ MIBG/Octreotide scan (includes Pheochromocytoma/ paraganglioma, extrapulmonary large/small cell)” ● Under subsequent Treatment Strategy, first line has been modified by adding parenthesis as follows: Restaging or monitoring response to active treatment (including immunotherapy)” ● Under subsequent Treatment Strategy, changed “not to be performed within 4 weeks of completion of therapy (ideally F-18 FDG, Ga-68 Dotatate, F-18 Fluciclovine PET is delayed 2–3 months after surgical therapy, 2–3 months after radiation therapy if locoregional assessment is the imaging goal), and/or evaluation for suspicion of recurrence due to new or changing signs/symptoms. (Asymptomatic surveillance is not approvable) (NCCN, 2018).” to “The interval should ideally be 6–12 weeks after surgery, and 12 weeks after radiation. PET can be performed 1–3 weeks after neoadjuvant chemotherapy or neoadjuvant chemoradiation to assess stage for surgery. PET evaluation can also be done for suspicion of recurrence due to new or changing signs/symptoms or rising tumor markers, or
--	--

	<p>inconclusive findings on CT. Asymptomatic surveillance is not approvable. (NCCN 2018, 2019)”</p> <ul style="list-style-type: none"> • List of cancers under subsequent imaging (without needing prior inconclusive imaging) has been changed. The following were removed: Breast cancer (female and males), colorectal cancer (including colon, rectal, appendiceal or anal cancer), ovarian cancer. The following were changed as follows: • “Lung cancer – Non small cell” to “Lung cancer – Non small cell and limited stage – small cell cancer” • “Esophageal cancer” to “Esophageal and esophagogastric cancer” • “Melanoma” to Melanoma – only stage III, IV (excludes uveal melanoma) • “Myeloma” to “Active Myeloma/plasmacytoma” • Added for Soft tissue sarcoma: “only stage II/III for response to neoadjuvant Rx” • Added Merkel cell carcinoma • Added “Mesothelioma, if also presurgical” • Individual References were removed for soft tissue sarcoma and vulvar/ vaginal cancer. • Statement regarding subsequent PET scans needing prior inconclusive imaging has been modified from “only” if other imaging (ie. US, CT, MRI, NM) is inconclusive in determining a treatment plan or unable to be performed “ to “ only if other imaging (ie. US, CT, MRI, NM) is inconclusive/ insufficient in determining a treatment plan or unable to be performed or with rising tumor markers and negative/ insufficient other imaging. PETCT is to be used only if the cancer is known to be generally F¹⁸-FDG, Ga⁶⁸-Dotatate, F¹⁸-Fluciclovine avid. It may be indicated if iodinated and gadolinium contrast are both contraindicated due to significant allergy or chronic renal failure without dialysis (NCCN 2019). “ • Under subsequent PET scans needing prior inconclusive imaging, the following were changed: <ul style="list-style-type: none"> ○ Added: Breast cancer (female and males), Bladder cancer, only if metastatic, Colorectal Cancer – resectable metastatic disease only, Anal/ Vulvar/ Penile Carcinoma, Bone Sarcoma, Sarcoma/ GIST/ Uterine/Rhabdomyosarcoma, Ovarian/ malignant germ cell tumors/primary peritoneal cancer – Stage II-IV, Endometrial cancer if candidate for surgery/locoregional therapy; Poorly differentiated Cancers, or
--	--

	<p>Dedifferentiated neuroendocrine tumors with prior negative Ga68-Dotatate/ MIBG/Octreotide scan</p> <ul style="list-style-type: none"> Removed: prostate cancer, pancreatic cancer, individual references for cancers Changed: "Lung cancer-Small cell" to "Extensive small cell lung cancer"; "Tumor of unknown Origin" to "Occult primary"; "Neuroendocrine cancer (e.g. carcinoid, pheochromocytoma, etc)" to "Poorly differentiated or dedifferentiated neuroendocrine tumors with prior negative Ga68-Dotatate/ MIBG/Octreotide scan (includes Pheochromocytoma/ paraganglioma, extrapulmonary large/small cell)" Last sentence has been changed from "Other malignancies where the tumor has been shown to be F¹⁸-FDG, Ga⁶⁸-Dotatate, F¹⁸-Fluciclovineavid on prior PET/CT imaging if done, and other imaging (ie: US, CT, MRI, NM) is inconclusive in determining a treatment plan or unable to be performed" to "Other malignancies where other imaging (i.e., US, CT, MRI, NM) is inconclusive in determining a treatment plan or unable to be performed." Under thyroid Cancer, <ul style="list-style-type: none"> Added references "(NCCN 2019, ATA 2015)" to subsequent treatment strategy for papillary/follicular/hurthle cancers <ul style="list-style-type: none"> Changed "Stimulated serum thyroglobulin > 2 ng/ml" to "Stimulated serum thyroglobulin > 5 ng/ml or high anti- thyroglobulin antibody (anti-Tg Ab) > 1 year after treatment (Na SJ 2012)" Changed "Current whole body I-131 scan is negative (Kloos, 2005)" to "Current stimulated whole body I-131/ I-123 scan is negative (Alzahranj 2012)" Changed "Medullary thyroid cancer when calcitonin levels > 150 pg/ml post-operatively (Wells, 2015)" to "Medullary thyroid cancer when calcitonin levels ≥ 150 pg/ml post primary treatment (NCCN 2019, Souteiro 2019)" Changed "Anaplastic 3-6 months after initial treatment, 3-6 month interval if persistent structural disease (Smallridge, 2012)" to "Anaplastic: Initial and Restaging after prior inconclusive/ insufficient CT/MRI (NCCN 2019)"
--	--

- ~~Added pediatric cancers section as follows: “PEDIATRIC CANCERS (for indications different from adult guidelines):~~
 - ~~Sarcoma Initial and Restaging (Quartuccio 2015)~~
 - ~~Neuroblastoma/ other cancers under Ga68 imaging: only with prior negative/ inconclusive MIBG/ Octreotide/ Ga68 PETCT (Uslu 2015, Alexander 2018, Kong 2016, Li 2018, Elkhatab 2017)~~
 - ~~Nasopharyngeal Cancer Initial staging after inconclusive/ insufficient MRI; Restaging. (Cheuk 2012)~~
- ~~For Gallium 68 Dotatate PET:~~
 - ~~Added references for initial or subsequent treatment strategy: (NCCN 2019, Deppen, 2016 a, b)~~
 - ~~Added under neuroendocrine tumors: “Medullary Thyroid Cancer for Initial staging; and Restaging when calcitonin \geq 150 pg/ml”~~
 - ~~Modified last part of the last sentence as follows: “and rising biomarkers (asymptomatic surveillance is not approvable).”~~
- ~~Under 18F-Fluciclovine PET/CT SCAN:~~
 - ~~Added “(Axumin)” after 18F-Fluciclovine~~
 - ~~Removed reference “(Bach-Gansmo, 2017)”~~
 - ~~Changed “18F-Fluciclovine PET/CT scans should be performed only if other imaging (CT, MRI, US, NM) is inconclusive/insufficient AND the patient has not already been evaluated with an F18-FDG, Ga68 Dotatate, F18-Fluciclovine PET/CT Scan” to “Known prostate cancer for workup of recurrence and response to treatment, only if other imaging (CT, MRI) AND Bone scan is inconclusive/insufficient. (NCCN 2019, Andriole 2019, Bach-Gansmo 2017)”~~
 - ~~Removed: “Known prostate cancer for workup of recurrence and response to treatment:”~~
 - ~~“Initial treatment by radical prostatectomy with” was replaced by “Post radical prostatectomy with”~~
 - ~~“Initial treatment radiation therapy with” was replaced by “Post radiation therapy with”~~
 - ~~“Post-RT rising PSA or positive digital exam and is candidate for local therapy” was replaced by “rising/persistent PSA (increase should be >2 ng/ml unless doubling time \leq 8 months or pt is a candidate for local salvage therapy)”~~

	<ul style="list-style-type: none">● Removed: “NOTE: Not all plans cover 18F-Fluciclovine (A9588), such as Magellan Complete Care of Florida and Magellan Complete Care of Arizona. If you are unsure, you should check with the Health Plan prior to requesting a PET with Fluciclovine from NIA.”● Added Background section as follows: <p>“BACKGROUND:</p> <p>Positron emission tomography (PET) is a rapidly developing and changing technology that is able to detect biochemical reactions, e.g., metabolism, or abnormal distribution of cell receptors within body tissues. A radioactive tracer is used during the procedure. Unlike other nuclear medicine examinations, PET can measure metabolic activity of the cells of body tissues, providing information about the functionality and structure of the particular organ or tissue examined. PET may also detect biochemical changes that help to evaluate malignant tumors and other lesions.</p> <p>The degree of radioactive tracer uptake may indicate increased metabolism in the cells of body tissues or an abnormal distribution of cell receptors. Cancer cells may show increased radioactive tracer relative to tissue not involved with tumor. Radioactive tracer uptake is often higher in fast growing tumors; PET is often not as beneficial for slow growing tumors. Radioactive tracer uptake may occur in various types of active inflammation and is not specific for cancer.”</p>
--	---

REFERENCES

1. NCCN Imaging Appropriate Use Criteria™. National Comprehensive Cancer Network (NCCN). Updated 2021. Accessed November 4, 2021. <https://www.nccn.org/professionals/imaging/default.aspx>
2. Radiological Society of North America. RSNA Statement on Gadolinium-Based MR Contrast Agents. Radiological Society of North America. Updated April 15, 2018. Accessed December 22, 2021. https://www.rsna.org/uploadedfiles/rsna/content/role_based_pages/media/rsna-gadolinium-position-statement.pdf

ADDITIONAL RESOURCES

1. American College of Radiology. ACR Appropriateness Criteria®. American College of Radiology (ACR). Updated 2021. Accessed December 22, 2021. <https://acsearch.acr.org/list>
2. American Society of Clinical Oncology. Ten things physicians and patients should question. Choosing Wisely Initiative ABIM Foundation. Updated July 26, 2021. Accessed December 22, 2021. <https://www.choosingwisely.org/societies/american-society-of-clinical-oncology/>
3. Araz M, Çayır D. (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth. *Mol Imaging Radionucl Ther*. Feb 5 2017;26(1):1-8. Diğer Tiroid Kanserleri için 18F-Fluorodeoksiglukoz-Pozitron Emisyon Tomografisi/Bilgisayarlı Tomografi: Medüller, Anaplastik, Lenfoma ve Fazlası. doi:10.4274/mirt.60783
4. Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. *J Urol*. Mar 2017;197(3 Pt 1):676-683. doi:10.1016/j.juro.2016.09.117
5. Bueno J, Landeras L, Chung JH. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios. *Radiographics*. Sep-Oct 2018;38(5):1337-1350. doi:10.1148/rg.2018180017
6. Gavrilă A. Thyroid cancer: Thyroid cancer that no longer responds to radioactive iodine may become sensitive after starting anti-cancer drugs. *Clin Thyroidology for the Public*. 2019;12(8):11-12.
7. Mayerhoefer ME, Prosch H, Beer L, et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. *Eur J Nucl Med Mol Imaging*. Jan 2020;47(1):51-60. doi:10.1007/s00259-019-04452-y
8. Savir-Baruch B, Banks KP, McConathy JE, et al. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine PET/CT for Recurrent Prostate Cancer. *Clin Nucl Med*. Dec 2018;43(12):909-917. doi:10.1097/rlu.0000000000002310
9. Castaldi P, Leccisotti L, Bussu F, Miccichè F, Rufini V. Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma. *Acta Otorhinolaryngol Ital*. Feb 2013;33(1):1-8.

10. Castroneves LA, Coura Filho G, de Freitas RMC, et al. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases. *J Clin Endocrinol Metab*. Sep 1 2018;103(9):3250-3259. doi:10.1210/je.2018-00193
11. Chagpar AB. How I treat breast cancer with positive lymph nodes. *Clin Adv Hematol Oncol*. Jul 2018;16(7):486-490.
12. Chatterjee A, Serniak N, Czerniecki BJ. Sentinel lymph node biopsy in breast cancer: a work in progress. *Cancer J*. Jan-Feb 2015;21(1):7-10. doi:10.1097/ppo.0000000000000090
13. Choi SJ, Jung KP, Lee SS, Park YS, Lee SM, Bae SK. Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody. *Nucl Med Mol Imaging*. Jun 2016;50(2):130-6. doi:10.1007/s13139-015-0378-5
14. Crispo F, Notarangelo T, Pietrafesa M, et al. BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. *Cancers (Basel)*. Sep 18 2019;11(9)doi:10.3390/cancers11091388
15. Deppen SA, Blume J, Bobbey AJ, et al. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. *J Nucl Med*. Jun 2016;57(6):872-8. doi:10.2967/jnumed.115.165803
16. Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. *J Nucl Med*. May 2016;57(5):708-14. doi:10.2967/jnumed.115.163865
17. Eary JF, Conrad EU. Imaging in sarcoma. *J Nucl Med*. Dec 2011;52(12):1903-13. doi:10.2967/jnumed.111.092999
18. Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary staging of breast cancer: what the radiologist should know. *Radiographics*. Oct 2013;33(6):1589-612. doi:10.1148/rg.336125060
19. Ehman EC, Johnson GB, Villanueva-Meyer JE, et al. PET/MRI: Where might it replace PET/CT? *J Magn Reson Imaging*. Nov 2017;46(5):1247-1262. doi:10.1002/jmri.25711
20. Fendler WP, Czernin J, Herrmann K, Beyer T. Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. *J Nucl Med*. Dec 2016;57(12):2016-2021. doi:10.2967/jnumed.116.174169
21. Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer. *J Nucl Med*. Feb 2016;57 Suppl 1:17s-26s. doi:10.2967/jnumed.115.157859
22. Hawkins MA, Aitken K. Image-guided radiotherapy for esophageal cancer. *Imaging Med*. 2012;4(5):515-25. doi:10.2217/iim.12.43
23. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. *J Clin Oncol*. May 1 2008;26(13):2155-61. doi:10.1200/jco.2007.14.5631

24. Ishii S, Shimao D, Hara T, et al. Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology? *Ann Nucl Med*. Apr 2016;30(3):225–33. doi:10.1007/s12149-015-1050-y
25. Kalemkerian GP. Staging and imaging of small cell lung cancer. *Cancer Imaging*. Jan 12 2012;11(1):253–8. doi:10.1102/1470-7330.2011.0036
26. Kanno S. Paraneoplastic neurologic syndrome: A practical approach. *Ann Indian Acad Neurol*. Jan 2012;15(1):6–12. doi:10.4103/0972-2327.93267
27. Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. *J Clin Oncol*. Apr 20 2010;28(12):2108–13. doi:10.1200/jco.2009.25.4151
28. Kreydin EI, Barrisford GW, Feldman AS, Preston MA. Testicular cancer: what the radiologist needs to know. *AJR Am J Roentgenol*. Jun 2013;200(6):1215–25. doi:10.2214/ajr.12.10319
29. Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM. Medullary Thyroid Carcinoma: An Update on Imaging. *J Thyroid Res*. 2019;2019:1893047. doi:10.1155/2019/1893047
30. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology*. Jul 2017;284(1):228–243. doi:10.1148/radiol.2017161659
31. Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. *AJR Am J Roentgenol*. Jun 2014;202(6):1316–29. doi:10.2214/ajr.13.11673
32. Mc CD, Gemignani ML. Current Management of the Axilla. *Clin Obstet Gynecol*. Dec 2016;59(4):743–755. doi:10.1097/grf.0000000000000232
33. Møller AK, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. *Oncologist*. 2012;17(9):1146–54. doi:10.1634/theoncologist.2011-0449
34. Moy L, Newell MS, Mahoney MC, et al. ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. *J Am Coll Radiol*. Nov 2016;13(11s):e43–e52. doi:10.1016/j.jacr.2016.09.023
35. Mueller WP, Melzer HI, Schmid I, Coppenrath E, Bartenstein P, Pfluger T. The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. *Eur J Nucl Med Mol Imaging*. Feb 2013;40(3):356–63. doi:10.1007/s00259-012-2278-6
36. P. D. Q. Pediatric Treatment Editorial Board. *Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version*. PDQ Cancer Information Summaries. National Cancer Institute (US); 2002.
37. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small Cell Lung Cancer Version 2.2022. National Comprehensive Cancer Network (NCCN). Updated November 24, 2021. Accessed December 7, 2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
38. Ospina MB, Horton J, Seida J, et al. *AHRQ Technology Assessments. Positron Emission Tomography for Nine Cancers (Bladder, Brain, Cervical, Kidney, Ovarian, Pancreatic, Prostate, Small Cell Lung, Testicular)*. Agency for Healthcare Research and Quality (US); 2008.

39. Parab TM, DeRogatis MJ, Boaz AM, et al. Gastrointestinal stromal tumors: a comprehensive review. *J Gastrointest Oncol*. Feb 2019;10(1):144-154. doi:10.21037/jgo.2018.08.20
40. Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. *Clin Cancer Res*. Dec 1 2013;19(23):6566-77. doi:10.1158/1078-0432.Ccr-13-1511
41. Quint LE. PET: other thoracic malignancies. *Cancer Imaging*. Oct 31 2006;6(Spec No A):S82-8. doi:10.1102/1470-7330.2006.9015
42. Rauscher I, Eiber M, Fürst S, et al. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. *J Nucl Med*. May 2014;55(5):724-9. doi:10.2967/jnumed.113.129247
43. Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. *Eur J Surg Oncol*. Jul 2014;40(7):794-804. doi:10.1016/j.ejso.2014.03.016
44. Robertson NL, Hricak H, Sonoda Y, et al. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. *Gynecol Oncol*. Mar 2016;140(3):420-4. doi:10.1016/j.ygyno.2016.01.011
45. Scheier BY, Lao CD, Kidwell KM, Redman BG. Use of Preoperative PET/CT Staging in Sentinel Lymph Node Positive Melanoma. *JAMA Oncol*. Jan 2016;2(1):136-7. doi:10.1001/jamaoncol.2015.3664
46. Sekine T, Barbosa FG, Sah BR, et al. PET/MR Outperforms PET/CT in Suspected Occult Tumors. *Clin Nucl Med*. Feb 2017;42(2):e88-e95. doi:10.1097/rlu.0000000000001461
47. Sherry SJ, Tahari AK, Mirpour S, Colucci A, Subramaniam RM. FDG-PET/CT in the evaluation of paraneoplastic neurologic syndromes. *Imaging Med*. 2014;6(1):117-26.
48. Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. *Cancer*. Sep 1 2011;117(17):3981-8. doi:10.1002/cncr.25991
49. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. *Thyroid*. Nov 2012;22(11):1104-39. doi:10.1089/thy.2012.0302
50. Songmen S, Nepal P, Olsavsky T, Sapire J. Axumin Positron Emission Tomography: Novel Agent for Prostate Cancer Biochemical Recurrence. *J Clin Imaging Sci*. 2019;9:49. doi:10.25259/jcis_139_2019
51. Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. *J Nucl Med*. Mar 2016;57(3):420-30. doi:10.2967/jnumed.115.158808
52. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. *J Nucl Med*. Jun 2010;51(6):875-82. doi:10.2967/jnumed.109.066134
53. Varadhachary GR, Raber MN. Cancer of unknown primary site. *N Engl J Med*. Aug 21 2014;371(8):757-65. doi:10.1056/NEJMra1303917

54. Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*. Jun 2015;25(6):567-610. doi:10.1089/thy.2014.0335

Disclaimer: National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

~~Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.~~